Key Highlights

● Amgen hosted an oncology webcast on October 24 tied to the ESMO congress.

● Second quarter revenue exceeded $10 billion, up 10%, and full-year guidance was raised.

● Repatha sales rose 37% to about $953 million, while Prolia and Xgeva fell 33%.

● Full-year non-GAAP earnings guidance was raised to between $22.30 and $23.50 per share.

Amgen (NASDAQ:AMGN), the biotechnology company and a member of the Nasdaq 100, hosted a webcast on Saturday, October 24, in conjunction with the European Society for Medical Oncology congress. According to the announcement the company issued on October 20, the session featured Murdo Gordon, who leads global markets, and Jean-Charles Soria, who oversees oncology in global development, along with other members of the management team.

The announcement said the discussion would cover the oncology portfolio and selected data presented at the congress. It did not name specific drugs or trial results. The context includes the company's latest quarterly results, its raised guidance, the performance of its main products, and the challenges it faces from biosimilars and from a crowded obesity field.

The most recent full earnings report came on August 4, so the oncology webcast is the freshest company-specific event with a verifiable record. The next quarterly report is expected in the coming weeks, though the date has not been confirmed.

What Did Amgen Announce for Its European Society for Medical Oncology Webcast?

In a release dated October 20, Amgen said it would host a webcast for the financial community on Saturday, October 24, at 11:30 a.m. Pacific time. The session was tied to the European Society for Medical Oncology congress, one of the largest annual gatherings for cancer researchers and drugmakers.

The speakers named in the announcement were Murdo Gordon, executive vice president of global markets and public affairs, and Jean-Charles Soria, senior vice president of oncology in global development. Other members of the management team were also expected to take part.

The company said the webcast would be broadcast live over the internet and open to news media and the general public, and that an archived replay would remain available for at least 30 days. A company webcast of this kind typically combines a review of presented data with a discussion of commercial plans.

The announcement did not specify which medicines or trial results would be covered.

How Big Is Oncology Within the Amgen Business, and Why Does ESMO Matter?

Amgen is best known for its cardiovascular, bone health, inflammation and rare disease medicines, but oncology has been a substantial part of the portfolio for decades. Its cancer products include Xgeva for preventing bone complications in patients with cancer, along with biologic and precision therapies and a growing set of biosimilars of oncology drugs.

The European Society for Medical Oncology congress is a major stage for cancer data. Companies present results from clinical trials there, and the information can influence prescribing habits and regulatory discussions. Presentations at the meeting are typically accompanied by company press releases and events like the one Amgen scheduled.

In the second quarter, the company reported that Prolia and Xgeva together generated about $1.1 billion of sales, a decline of 33% because of biosimilar competition. That figure shows why the company is working to expand other franchises and to replace revenue from products whose exclusivity has ended.

Oncology activity at a congress is therefore part of a broader effort to rebuild growth drivers. The success of that effort will depend on trial outcomes, regulatory decisions and competition, none of which can be judged from a webcast announcement alone.

What Did Amgen Report for Its Second Quarter on August 4?

According to published summaries of the company's second quarter call, Amgen's total revenue exceeded $10 billion, an increase of 10% from a year earlier. The non-GAAP operating margin was 48%, and non-GAAP cost of sales was 19.6% of product sales.

Free cash flow in the quarter was about $3.5 billion. Capital expenditures were about $500 million in the quarter, and the company expects roughly $2.6 billion for the full year. The quarterly dividend was set at $2.52 per share, an increase of 6%.

A margin near the high forties is high for a large drugmaker and reflects the profile of biologic medicines with relatively low cost of goods. It also means that changes in product mix, such as a shift toward biosimilars with lower prices, can move the company's results visibly.

These figures come from published call summaries and not from the full earnings release. Cash and debt balances and tariff effects were not available from those summaries.

Which Amgen Products Are Driving Growth, and Which Are Under Pressure?

Repatha, the cholesterol-lowering injection, generated about $953 million, up 37%. Evenity, a treatment for osteoporosis in postmenopausal women at high risk of fracture, produced about $714 million, up 38%. Tezspire, partnered with AstraZeneca for severe asthma, brought in about $486 million, up 42%.

Uplizna, approved for several rare autoimmune conditions, rose 90% to about $335 million. These four products form a group of newer or expanding medicines that give the company a sizable base of growth outside its older franchises.

On the other side, Prolia and Xgeva fell 33% as biosimilars entered the market. That is a large decline in two long-standing products, and it is the main reason total growth is 10% and not higher.

The company also has a biosimilar portfolio of its own, which generated about $855 million, up 29%, with Pavblu, a biosimilar of an eye disease injection, contributing about $287 million, up 121%. In other words, Amgen is both a victim and a beneficiary of biosimilar competition.

What Guidance Did Amgen Raise for the Full Year?

Following the second quarter, Amgen raised its full-year revenue guidance to between $38.2 billion and $39.4 billion. Non-GAAP earnings per share guidance was raised to between $22.30 and $23.50.

The width of the ranges, roughly $1.2 billion for revenue and $1.20 for earnings, reflects normal uncertainty about demand, pricing and the timing of expenses. With the third quarter report still ahead, the company may narrow or shift those ranges.

Raised guidance is encouraging by its nature, but it is also an expectation and not a result. Biotechnology companies face quarter-to-quarter variability from wholesaler inventory, insurance coverage resets at the start of the year, and changes in rebates. These items often explain why a quarter looks different from what a simple run rate would indicate.

Where Does the Amgen Obesity Candidate MariTide Stand?

MariTide, Amgen's lead obesity candidate, is in a broad late-stage development program. The call summaries state that nine late-stage trials are ongoing, and that a data package is expected within the year. Its dosing schedule is a point of interest because weekly injections are the current standard among marketed products.

Obesity is the most closely watched area in the pharmaceutical industry, with Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) leading in sales. A newcomer has to demonstrate meaningful weight loss, acceptable tolerability and a dosing schedule that provides a real advantage. Trial results could therefore influence sentiment about Amgen more than most other pipeline events.

Research and development spending is expected to grow at a high single-digit rate this year, partly to fund the late-stage obesity program. Outcomes are uncertain, and large trials can produce disappointing as well as encouraging results.

What Challenges Does Amgen Face From Biosimilars, Pricing and Trade Measures?

The most visible challenge is biosimilar competition, which has cut sales of Prolia and Xgeva by a third. Enbrel, another long-standing product, is also exposed to pricing and competitive pressures.

A second challenge is government pricing. The United States has been moving toward negotiated Medicare prices for selected drugs, and Amgen has products among those subject to the process. The effect depends on rules that have evolved over time, and the company has described it as a headwind to net prices in its filings.

A third is trade and tariffs. Biotechnology companies manufacture in several countries, including the United States and Puerto Rico, and changes to tariff rules can affect cost structure. The company has said it is expanding American manufacturing capacity.

A fourth challenge is execution on the pipeline. Obesity, oncology and inflammation programs all require large trials and regulatory success, and clinical setbacks are common in the industry. A mix of steady cash generation and uncertain pipeline outcomes is typical for large biotechnology companies.

What Is Next for Amgen After the ESMO Webcast?

The next scheduled event is the third quarter earnings report, which the company has in prior years issued in early November.

Items likely to draw attention include the sales trend for Repatha and Evenity, the pace of the Prolia and Xgeva decline, the contribution of biosimilars, any change to full-year guidance, and updates on MariTide enrollment and data timing.

Further regulatory milestones may also arrive, since Amgen has multiple applications in review at agencies in the United States, Europe and Japan. Approvals and label expansions can come at any time and are usually announced by press release.

How Does Amgen Compare With Other Biotechnology Companies Reporting This Season?

Large biotechnology companies are reporting a split picture this season. Newer products in cardiovascular, immunology and neuroscience are growing quickly, while older franchises face generic and biosimilar erosion. Amgen's 10% revenue growth places it in the middle of that range, behind the fastest growers in obesity and ahead of companies with larger patent expirations.

Margin metrics also vary. A non-GAAP operating margin of 48% is high even among large drugmakers, and free cash flow of about $3.5 billion in a quarter supports the dividend and capital spending. The company's debt load rose after the acquisition of Horizon Therapeutics.

Competitive dynamics differ by product. Repatha competes with other cholesterol therapies, including oral options that are under development, while Tezspire competes in respiratory biologics with several large rivals. Each market has its own pricing and reimbursement landscape.

As a result, sector comparisons are best made product by product and not at the level of the whole company. The oncology webcast was a reminder that a diversified biotechnology business is a collection of franchises, each at a different stage of its life.